A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

• Status: NOT_YET_RECRUITING
• Trial end date: 2031-08-01

Summary

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

• Phase: PHASE3

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: orforglipron